FCI-Glioblastoma Study
ConditionGlioblastom WHO Grade 4
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorUniversity of Aberdeen
About this trial
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is:
• Can FCI differentiate glioblastoma progression from pseudo-progression?
Participants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.
Eligibility criteria
Qualifiers
Patients scheduled to have standard adjuvant temozolomide treatment for glioblastoma, within four weeks following radical radiotherapy with concomitant temozolomide
18 to 70 years old
Life expectancy at least 12 weeks
Able to undergo MRI scans lasting up to 1 hour each
Disqualifiers
Previous treatment for glioblastoma other than surgery and chemoradiation.
Previous radiotherapy to brain and/or prior chemotherapy for lower grade glioma.
Planned additional treatment with Tumor-Treating Fields
Previous cytotoxic wafers or implants at the time of neurosurgery
Trial design
Treatments tested in this trial
- Baseline Field-Cycling Imaging research scan
- Baseline 3T MRI research scan
- Second Field-Cycling Imaging research scan
- Second 3T MRI research scan
- Final Field-Cycling Imaging research scan
- Final 3T MRI research scan
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Aberdeen
Lead sponsor
NHS Grampian
Collaborator
Source ClinicalTrials.gov